VP of Research & Policy, Ewing Marion Kauffman Foundation
Founding Director, Massachusetts Technology Transfer Center
Co-Founder and CEO, DNAnexus
Managing director, the Foundry Group
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
President & CEO, Indiana Biosciences Research Institute
Software Engineer at Skelmir
VP of Research & Policy, Ewing Marion Kauffman Foundation
Austin—Magnitude Software is selling a $179 million stake in the company to London-based private equity firm 3i Group.
Chris Ney, the founder, chairman, and CEO of Magnitude, is investing alongside 3i, the company announced. The company didn’t say whether the... Read more »
Flipside Crypto, a Boston startup developing analytics for cryptocurrencies, has landed its main metric onto CoinMarketCap and other financial websites including MarketWatch, TheStreet and Stocktwits, the company says.
Founded in 2017, Flipside says its Fundamental Crypto Asset Score—FCAS for short—rates the... Read more »
Houston—Tom Luby, the head of JLabs in Houston, has been named the new director of the Texas Medical Center’s Innovation Institute, the center announced Monday morning.
Luby takes over the innovation institute three months after former director Erik Halvorsen left... Read more »
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.
In the early... Read more »
There’s robotics news, clinical research companies raising cash, and plenty of early-stage venture capital money moving in the Boston technology world this week. Read on for more:
—Via Separations, a startup developing energy-efficient filtration technology, has raised $4.8 million in a... Read more »
San Antonio—Ben Kuhn has been promoted to become the CEO of Keen, a San Antonio startup that helps software developers with custom application programming interfaces for data collection and analytics.
Kuhn was hired as the general manager of Keen in... Read more »
Our annual half-day life sciences variety show, “What’s Hot in Biotech,” is back. Join Xconomy on May 21 at Bristol-Myers Squibb’s brand new offices in Kendall Square for a series of candid discussions, in a variety of formats, on... Read more »
X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there.
Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business... Read more »
John Maraganore, CEO of Alnylam Pharmaceuticals; Penny Heaton, CEO of the Bill & Melinda Gates Medical Research Institute; digital health leader Pear Therapeutics; and renowned women-in-science advocate and MIT professor emerita Nancy Hopkins. These outstanding leaders were among the winners of... Read more »
TriNetX, a Cambridge, MA, developer of data analytics software for clinical research, has raised $40 million in a Series D funding round led by Merck’s corporate venture capital fund, the company said.
The company’s analytics platform helps pharma companies detail the... Read more »
Austin—If you’re a startup talking up your artificial intelligence chops in your venture capital pitch, you’re not alone.
For Cisco Investments, the venture arm of tech giant Cisco, artificial intelligence is no longer one of the key trends to watch... Read more »
[Updated 3/13/19, 12:20pm. See below.] With public and political winds blowing in the same direction, significant reform of the complicated U.S. drug-pricing system seems ever more likely. One part of the system that the Trump administration wants to overhaul... Read more »
Last summer, dozens of former Jibo employees returned to the defunct company’s Boston offices for a long weekend of pizza, beer, and brainstorming. The task: How do you teach the company’s “social robot” to say goodbye?
Rich Sadowsky, Jibo’s former head... Read more »
George Golumbeski is one of the most prolific dealmakers in the biopharmaceutical world. But the deal that changed his life is a pact he made with himself when he was ten years old.
Playing with friends in front of his house... Read more »
It’s been more than three years since the FDA approved salmon from AquaBounty Technologies, but debates about labels and other requirements have kept the genetically engineered fish from reaching dining plates. On Friday, the FDA removed the last regulatory hurdle standing... Read more »
In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration, which is the most powerful regulator of medical products in the world.
It wasn’t a high bar to clear. Libertarians... Read more »
The Amazon, Berkshire Hathaway, and JPMorgan-led healthcare moonshot has a name. The venture capital dollars continued to roll in for A.I. startups. The Akamai-Janrain deal was pegged at $125 million. And a local VC firm is reloading for a new fund.... Read more »
A few years ago, the frothiest market in tech was arguably startups selling subscriptions to boxes of curated goods, such as clothing, beauty products, and food, which would arrive on customers’ doorsteps each month.
The buzz around this area of... Read more »
Much has been said about Lyft’s early lead over Uber in the “horserace” to become the first ride-hailing app company to go public. But now that San Francisco-based Lyft has filed its 276-page IPO prospectus with the U.S. Securities and Exchange... Read more »
Al Gore may just be on the side of the Luddites.
Yes, that’s the radical faction of British textile workers at the onset of the Industrial Revolution who broke into factories to smash the new machines that they feared would... Read more »
Even as the executive order President Trump issued last month on artificial intelligence furthered the conversation about a developing national strategy for the sector, it was met with certain criticism. A common complaint was that the plan won’t implement itself.
“The... Read more »
Erasca, a biotech startup run by the former CEO of Ignyta, debuted in December with $42 million and an audacious plan to “erase cancer,” but provided little explanation as to how.
Erasca is still keeping many of those details under wraps.... Read more »
Sponsored · Whitepaper
Keep easily accessible, historical records to aid in root cause analysis for deviations
XiltriX
From Our Editors · Special Report
Facing an Uncertain Future
Xconomy
Sponsored · Whitepaper
Implementing a reliable and auditable monitoring program for life science samples, assets & equipment
XiltriX
Professor of Management at Sloan School, MIT
Founder and Managing Partner, Boston Millennia Partners
Founder, DEKA Research and Development Corporation
Co-creator, TEDMED
Professor of Chemistry, Tufts University
CEO, CyPhy Works
Co-Founder and Director, Boston Scientific Corporation
Professor, MIT Sloan School of Management
Distinguished Lecturer, Sloan School of Management at MIT
Founder, CEO, Managing Partner, Flagship Ventures
Professor of the Practice, New Media Medicine, MIT Media Lab
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
